Endogenous TPC2-like currents in response to PI(3,5)P2 have also been characterized in adult fibroblasts confirming gain-of-function variants [70,71], as well as in human melanocyte [73] and mouse liver cancer [66] cell lines in which TPC2 was targeted using CRISPR/Cas9. Here, TPCN2 is linked to liver cancer.